Last edition
News about "KRAS G12D inhibitor "
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
KRAS G12D Inhibitor | 12/05/2026 | By News Bureau | 107
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
KRAS G12D Inhibitor | 19/01/2026 | By News Bureau | 529
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
KRAS G12D Inhibitor | 11/10/2025 | By Dineshwori | 721
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy